{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:24:12Z","timestamp":1648513452598},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1991,9,1]],"date-time":"1991-09-01T00:00:00Z","timestamp":683683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[1991,9,1]],"date-time":"1991-09-01T00:00:00Z","timestamp":683683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Oncol. & Tumor Pharmacother."],"published-print":{"date-parts":[[1991,9]]},"DOI":"10.1007\/bf02987173","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T18:21:13Z","timestamp":1631902873000},"page":"155-158","source":"Crossref","is-referenced-by-count":0,"title":["Prevention of chemotherapy-induced leukemia and of leukemia relapses"],"prefix":"10.1007","volume":"8","author":[{"given":"Emil J.","family":"Freireich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02987173_CR1","first-page":"35","volume-title":"Therapy of Hematopoietic Neoplasia","author":"M Beran","year":"1991","unstructured":"Beran M: Treatment of myelodysplastic syndromes, in Kantarjian H M, Frei reich E J (eds):Therapy of Hematopoietic Neoplasia, pp. 35\u201382. New York, Marcel Dekker (1991)."},{"key":"BF02987173_CR2","first-page":"203","volume":"1","author":"E H Estey","year":"1987","unstructured":"Estey E H, Keating M J, Dixon D O, Trujillo J M, McCredie K B, Freireich E J: Karyotype is prognostically more important than the FAB system\u2019s distinction between myelodysplastic syndrome and acute myelogenous leukemia.Hematol Path\n                  1, 203 (1987).","journal-title":"Hematol Path"},{"key":"BF02987173_CR3","first-page":"105","volume-title":"Therapy of Hematopoietic Neoplasia","author":"H M Kantarjian","year":"1991","unstructured":"Kantarjian H M, Talpaz M: Treatment of chronic myelogenous leukemia, in Kantarjian H M, Freireich E J (eds):Therapy of Hematopoietic Neoplasia, pp. 105\u2013174. New York, Marcel Dekker (1991)."},{"key":"BF02987173_CR4","first-page":"1","volume-title":"Therapy of Hematopoietic Neoplasia","author":"E H Estey","year":"1991","unstructured":"Estey E H, Freireich E J: Therapy for acute myelogenous leukemia, in Kantarjian H M, Freireich E J (eds):Therapy of Hematopoietic Neoplasia, pp. 1\u201333. New York, Marcel Dekker, (1991)."}],"container-title":["Medical Oncology and Tumor Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02987173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02987173\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02987173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T19:41:41Z","timestamp":1631907701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02987173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,9]]},"references-count":4,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1991,9]]}},"alternative-id":["BF02987173"],"URL":"https:\/\/doi.org\/10.1007\/bf02987173","relation":{},"ISSN":["0736-0118"],"issn-type":[{"value":"0736-0118","type":"print"}],"subject":[],"published":{"date-parts":[[1991,9]]}}}